HIV-1 Nef-mediated downregulation of CD155 results in viral restriction by KIR2DL5+ NK cells.


Journal

PLoS pathogens
ISSN: 1553-7374
Titre abrégé: PLoS Pathog
Pays: United States
ID NLM: 101238921

Informations de publication

Date de publication:
06 2022
Historique:
received: 03 11 2021
accepted: 05 05 2022
entrez: 24 6 2022
pubmed: 25 6 2022
medline: 29 6 2022
Statut: epublish

Résumé

Antiviral NK cell activity is regulated through the interaction of activating and inhibitory NK cell receptors with their ligands on infected cells. HLA class I molecules serve as ligands for most killer cell immunoglobulin-like receptors (KIRs), but no HLA class I ligands for the inhibitory NK cell receptor KIR2DL5 have been identified to date. Using a NK cell receptor/ligand screening approach, we observed no strong binding of KIR2DL5 to HLA class I or class II molecules, but confirmed that KIR2DL5 binds to the poliovirus receptor (PVR, CD155). Functional studies using primary human NK cells revealed a significantly decreased degranulation of KIR2DL5+ NK cells in response to CD155-expressing target cells. We subsequently investigated the role of KIR2DL5/CD155 interactions in HIV-1 infection, and showed that multiple HIV-1 strains significantly decreased CD155 expression levels on HIV-1-infected primary human CD4+ T cells via a Nef-dependent mechanism. Co-culture of NK cells with HIV-1-infected CD4+ T cells revealed enhanced anti-viral activity of KIR2DL5+ NK cells against wild-type versus Nef-deficient viruses, indicating that HIV-1-mediated downregulation of CD155 renders infected cells more susceptible to recognition by KIR2DL5+ NK cells. These data show that CD155 suppresses the antiviral activity of KIR2DL5+ NK cells and is downmodulated by HIV-1 Nef protein as potential trade-off counteracting activating NK cell ligands, demonstrating the ability of NK cells to counteract immune escape mechanisms employed by HIV-1.

Identifiants

pubmed: 35749424
doi: 10.1371/journal.ppat.1010572
pii: PPATHOGENS-D-21-02208
pmc: PMC9231786
doi:

Substances chimiques

Antiviral Agents 0
Ligands 0
Receptors, Natural Killer Cell 0
Receptors, Virus 0
nef Gene Products, Human Immunodeficiency Virus 0
nef protein, Human immunodeficiency virus 1 0
nef protein, Human immunodeficiency virus 2 0
poliovirus receptor 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

e1010572

Déclaration de conflit d'intérêts

The authors have declared that no competing interests exist.

Références

Sci Rep. 2017 May 25;7(1):2414
pubmed: 28546555
PLoS Med. 2015 Nov 17;12(11):e1001900; discussion e1001900
pubmed: 26575988
AIDS Res Hum Retroviruses. 2017 Feb;33(2):93-100
pubmed: 27296670
AIDS. 2017 Nov 13;31(17):2317-2330
pubmed: 28926399
J Acquir Immune Defic Syndr. 2016 May 1;72(1):1-10
pubmed: 26656785
J Virol. 2012 Mar;86(5):2715-28
pubmed: 22190722
J Immunol. 2000 Jun 1;164(11):5797-804
pubmed: 10820258
J Virol. 1994 May;68(5):2906-14
pubmed: 8151761
Retrovirology. 2013 Dec 03;10:146
pubmed: 24299076
J Exp Med. 2003 Aug 18;198(4):557-67
pubmed: 12913096
J Immunol. 2004 Apr 1;172(7):3994-8
pubmed: 15034010
Blood. 2003 Sep 15;102(6):2130-7
pubmed: 12775570
J Exp Med. 1994 Jan 1;179(1):115-23
pubmed: 7903679
J Gen Virol. 2013 Dec;94(Pt 12):2664-2669
pubmed: 24045107
J Immunol. 2004 Jun 15;172(12):7385-92
pubmed: 15187115
Hum Immunol. 2014 Aug;75(8):816-21
pubmed: 24929143
J Immunol. 1998 Jul 15;161(2):571-7
pubmed: 9670929
Med Microbiol Immunol. 2017 Dec;206(6):463-470
pubmed: 29032460
mBio. 2019 Jun 18;10(3):
pubmed: 31213558
Cell Host Microbe. 2016 May 11;19(5):686-95
pubmed: 27173934
Immunity. 1999 Jun;10(6):661-71
pubmed: 10403641
Nature. 1998 Jan 22;391(6665):397-401
pubmed: 9450757
Cell Host Microbe. 2016 May 11;19(5):570-1
pubmed: 27173922
Int J Mol Sci. 2020 Jan 30;21(3):
pubmed: 32019260
Immunity. 1995 Dec;3(6):801-9
pubmed: 8777725
Proc Natl Acad Sci U S A. 2009 Oct 20;106(42):17858-63
pubmed: 19815499
J Virol. 1986 Aug;59(2):284-91
pubmed: 3016298
Croat Med J. 2007 Dec;48(6):800-6
pubmed: 18074414
PLoS One. 2018 Jan 23;13(1):e0191733
pubmed: 29360870
PLoS Pathog. 2012;8(7):e1002805
pubmed: 22807681
Proc Natl Acad Sci U S A. 2013 Apr 23;110(17):6626-33
pubmed: 23542380
Viruses. 2017 Oct 12;9(10):
pubmed: 29023371
Front Immunol. 2012 Sep 17;3:289
pubmed: 23060877
J Gen Virol. 2007 Jan;88(Pt 1):242-250
pubmed: 17170457
J Immunol. 1989 May 1;142(9):3320-8
pubmed: 2785140
Mol Cell Proteomics. 2019 Nov;18(11):2310-2323
pubmed: 31308249
J Immunol Res. 2021 Jan 13;2021:9053280
pubmed: 33521134
Nat Rev Immunol. 2015 Apr;15(4):243-54
pubmed: 25743219
Front Immunol. 2012 Aug 20;3:258
pubmed: 22934097
Nature. 2008 Jan 24;451(7177):425-30
pubmed: 18200009
J Immunol Methods. 2004 Nov;294(1-2):15-22
pubmed: 15604012
Nat Immunol. 2016 Sep;17(9):1067-74
pubmed: 27455421
J Virol. 2012 Apr;86(8):4496-504
pubmed: 22301152
AIDS. 2014 Jun 19;28(10):1399-408
pubmed: 24785948
Cell. 2020 Aug 20;182(4):1027-1043.e17
pubmed: 32822567
J Virol. 2019 Sep 30;93(20):
pubmed: 31375574
J Virol. 2001 Apr;75(8):3657-65
pubmed: 11264355
J Virol. 2002 May;76(9):4625-33
pubmed: 11932428
J Cell Biol. 2004 Dec 6;167(5):903-13
pubmed: 15569716
Annu Rev Immunol. 2013;31:163-94
pubmed: 23298212
J Immunol. 2007 Apr 1;178(7):4402-10
pubmed: 17371997
AIDS. 2020 May 1;34(6):801-813
pubmed: 32028328
Nat Immunol. 2019 Sep;20(9):1129-1137
pubmed: 31358998
Front Immunol. 2018 Oct 10;9:2341
pubmed: 30364127
Semin Immunol. 2006 Jun;18(3):145-50
pubmed: 16740393
J Virol. 2007 Dec;81(24):13852-64
pubmed: 17928336
Cancer Immunol Res. 2015 Jun;3(6):575-82
pubmed: 26041808
Front Cell Infect Microbiol. 2020 May 05;10:175
pubmed: 32432050
J Immunother Cancer. 2020 Sep;8(2):
pubmed: 32900861
Virology. 2014 Sep;464-465:375-384
pubmed: 25113908
Annu Rev Immunol. 2013;31:227-58
pubmed: 23516982

Auteurs

Pia Fittje (P)

Leibniz Institute of Virology (LIV), Hamburg, Germany.

Angelique Hœlzemer (A)

Leibniz Institute of Virology (LIV), Hamburg, Germany.
First Department of Internal Medicine, Division of Infectious Diseases, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
German Center for Infection Research (DZIF), Partner Site Hamburg-Lübeck-Borstel-Riems, Hamburg, Germany.

Wilfredo F Garcia-Beltran (WF)

Leibniz Institute of Virology (LIV), Hamburg, Germany.
Department of Pathology, Massachusetts General Hospital/Harvard Medical School, Boston, Massachusetts, United States of America.

Sarah Vollmers (S)

Leibniz Institute of Virology (LIV), Hamburg, Germany.

Annika Niehrs (A)

Leibniz Institute of Virology (LIV), Hamburg, Germany.

Kerri Hagemann (K)

Leibniz Institute of Virology (LIV), Hamburg, Germany.

Glòria Martrus (G)

Leibniz Institute of Virology (LIV), Hamburg, Germany.

Christian Körner (C)

Leibniz Institute of Virology (LIV), Hamburg, Germany.

Frank Kirchhoff (F)

Institute of Molecular Virology, Ulm University Medical Center, Ulm, Germany.

Daniel Sauter (D)

Institute for Medical Virology and Epidemiology of Viral Diseases, University Hospital Tübingen, Tübingen, Germany.

Marcus Altfeld (M)

Leibniz Institute of Virology (LIV), Hamburg, Germany.
German Center for Infection Research (DZIF), Partner Site Hamburg-Lübeck-Borstel-Riems, Hamburg, Germany.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH